How many drugs treat Ocular hypertension?

Drug Landscape tracks 10 marketed treatments for Ocular hypertension (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Ocular hypertension?

Most recent: Alphagan — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/ocular-hypertension.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ocular hypertension — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ocular hypertension (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ocular hypertension, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vyzulta	LATANOPROSTENE BUNOD	Bausch Health		Prostaglandin F2-alpha receptor	2017-01-01
Rhopressa	NETARSUDIL	Alcon Labs Inc	Rho Kinase Inhibitor	rho kinase	2017-01-01
Betaxon	LEVOBETAXOLOL	Alcon Pharms Ltd	levobetaxolol	Beta-1 adrenergic receptor	2000-01-01
Azopt	BRINZOLAMIDE	Novartis	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
Alphagan	BRIMONIDINE TARTRATE	Senju Pharmaceutical Co., Ltd	alpha-Adrenergic Agonist	Alpha-2C adrenergic receptor	1996-01-01
Alphagan	BRIMONIDINE	Senju Pharmaceutical Co., Ltd	alpha-Adrenergic Agonist	Alpha-2C adrenergic receptor	1996-01-01
Xalatan	LATANOPROST	Thea Pharma	Prostaglandin Analog [EPC]	Prostaglandin F2-alpha receptor	1996-01-01
Trusopt	DORZOLAMIDE	Merck & Co.	Carbonic Anhydrase Inhibitor	Carbonic anhydrase 2	1994-01-01
Taxol	nab-paclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Taxol	paclitaxel	Pfizer	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-07 — Alphagan · FDA · approved · US
2026-04-16 — Alphagan · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Ocular hypertension
Pfizer · 3 drugs in Ocular hypertension
Novartis · 3 drugs in Ocular hypertension
Bausch Health · 2 drugs in Ocular hypertension
Alcon Research · 2 drugs in Ocular hypertension
Baxter · 2 drugs in Ocular hypertension
Senju Pharmaceutical Co., Ltd · 2 drugs in Ocular hypertension
Merck & Co. · 1 drug in Ocular hypertension
Michael D. Straiko, MD · 1 drug in Ocular hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in Ocular hypertension
The First Affiliated Hospital with Nanjing Medical University · 1 drug in Ocular hypertension
Thea Pharma · 1 drug in Ocular hypertension

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ocular hypertension:

Cite this brief

Drug Landscape (2026). Ocular hypertension — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ocular-hypertension. Accessed 2026-06-10.

Ocular hypertension full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing